Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

GCC-AP0341: Green Cross' eosinophilia inhibitor

June 28, 1996

5-lipoxygenase and cyclooxygenase inhibitors from Abbott

June 28, 1996

Abbott discloses 5-lipoxygenase inhibitors

June 28, 1996

Leukotriene biosynthesis inhibitors from Merck Frosst

June 28, 1996

Proctor & Gamble acquires Dura products

June 28, 1996

Thymosin beta4 as cystic fibrosis treatment

June 21, 1996

Astra's Pulmicort approaches FDA approval

June 21, 1996

B2 antagonists from Servier

June 21, 1996

Ono reveals antioxidant TxA2 synthase/5-lipoxygenase inhibitors

June 21, 1996

Chymase/NO production inhibitors synthesized by Wakamoto

June 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...